A genetically immortalized human stem cell line: a promising new tool for Alzheimer's disease therapy

Authors

  • Nicha Puangmalai King’s College London, Wolfson Centre for Age-Related Diseases, London, SE1 1UL, UK; Research Center for Neuroscience, Institute of Molecular Biosciences, Mahidol University, Salaya, Nakhonpathom 73170, Thailand
  • Alyma Somani King’s College London, Wolfson Centre for Age-Related Diseases, London, SE1 1UL, UK
  • Wipawan Thangnipon Research Center for Neuroscience, Institute of Molecular Biosciences, Mahidol University, Salaya, Nakhonpathom 73170, Thailand
  • Clive Ballard King’s College London, Wolfson Centre for Age-Related Diseases, London, SE1 1UL, UK
  • Martin Broadstock King’s College London, Wolfson Centre for Age-Related Diseases, London, SE1 1UL, UK

DOI:

https://doi.org/10.17179/excli2015-560

Keywords:

Alzheimer's disease, cell viability, CTX0E03 cell line, neural stem cell, okadaic acid, oligomeric amyloid-ß

Abstract

Amyloid-β peptides and hyper-phosphorylated tau are the main pathological hallmarks of Alzheimer's disease (AD). Given the recent failure of several large-scale clinical trials and the lack of disease-modifying pharmacological treatments, there is an urgent need to develop alternative therapies. A clinical grade human CTX0E03 neural stem cell line has recently passed phase I trials in people with stroke. However, this cell line has not been investigated in other neurodegenerative disorders. This study investigates the survival of CTX0E03 cells under conditions based on the underlying AD pathology. Cell viability assays showed a concentration dependence of this cell line to the toxic effects of Aβ1-42, but not Aβ1-40, and okadaic acid, a phosphatase 2A inhibitor. Notably, CTX0E03 cell line displayed toxicity at concentrations significantly higher than both rat neural stem cells and those previously reported for primary cultures. These results suggest CTX0E03 cells could be developed for clinical trials in AD patients.

Downloads

Published

2015-10-21

How to Cite

Puangmalai, N., Somani, A., Thangnipon, W., Ballard, C., & Broadstock, M. (2015). A genetically immortalized human stem cell line: a promising new tool for Alzheimer’s disease therapy. EXCLI Journal, 14, 1135–1114. https://doi.org/10.17179/excli2015-560

Issue

Vol. 14 (2015)

Section

Original articles

License

Authors who publish in this journal agree to the following terms:

  • The authors keep the copyright and grant the journal the right of first publication under the terms of the Creative Commons Attribution license, CC BY 4.0. This licencse permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited.
  • The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
  • Because the advice and information in this journal are believed to be true and accurate at the time of publication, neither the authors, the editors, nor the publisher accept any legal responsibility for any errors or omissions presented in the publication. The publisher makes no guarantee, express or implied, with respect to the material contained herein.
  • The authors can enter into additional contracts for the non-exclusive distribution of the journal's published version by citing the initial publication in this journal (e.g. publishing in an institutional repository or in a book).

Most read articles by the same author(s)